Info

Hepaticus, Inc. develops and commercializes products that accurately model human liver function in order to advance pharmaceutical development. We aim to advance pharmaceutical development for our partners with a proprietary human liver surrogate. Hepaticus produces small animal models containing functioning human liver cells. These animals serve as accurate models of human liver diseases such as hepatitis C, enabling the efficient development of treatments for devastating liver disorders. The same core technology produces robust models of human liver function, critical in the development process of all drugs in order to identify and modify compounds that may pose liver toxicity problems. Hepaticus participates in both the liver drug development and predictive toxicology markets. Competing models of human liver function are severely limited. Existing cell-based and animal models are high cost, immune-suppressed, too fragile to ship to customer sites, and do not consistently predict human disease or the potential failure of drugs due to liver toxicity. These limitations have slowed the pace of drug discovery and contributed to the fact that 40% of all drug failures are due to liver toxicity, undetected in the drug development process. Our products are designed to open this bottleneck. Accurately modeling human liver functionality and delivering this functionality reliably unlocks immediate business opportunities for Hepaticus and its partners. Hepaticus, Inc. is based on the research of Drs. George and Catherine Wu, professors at the University of Connecticut Health Center. Hepaticus holds an exclusive license to the worldwide issued patent covering the proprietary technology. Hepaticus, Inc. is privately held and was established in 2003. The company's facilities are located in Connecticut.